ClinicalTrials.gg
Sign In
CompletedNCT03832647Updated Oct 18, 2021

Anti-acne Efficacy of a Dermo-cosmetic Product Associated With the Fixed Combination Adapalene 0.1%/ Benzoyl Peroxide 2.5% Treatment Versus This Treatment Associated With a Standard Moisturizer in Male and Female Subjects Presenting With Mild to Moderate Acne

A Phase 4 interventional study of Epiduo and Salicylic Acid in Acne, sponsored by Vichy Laboratoires. Completed at 1 site in France. Open to participants aged 16 Years to 35 Years. Per ClinicalTrials.gov, last updated 2021-10-18.

Sponsored by Vichy Laboratoires · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
16 Years to 35 Years
Sex
All
01

Study summary

Study to evaluate the anti-acne efficacy of a dermo-cosmetic associated with the fixed combination Adapalene 0.1%/ benzoyl peroxide 2.5% treatment and to demonstrate that the dermo-cosmetic product can improve the local tolerance of the fixed combination Adapalene 0.1%/ benzoyl peroxide 2.5% treatment

Multi centre, Randomised, Double blind, Controlled, Parallel (100 subjects per arm), Intra-subject \& inter subject comparisons

02

Conditions studied

  • Acne

Browse trials for

03

In context

Acne Vulgaris

790 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

This study's enrollment of 200 is above the median of 70 across 672 interventional studies indexed under Acne Vulgaris.

Browse Acne Vulgaris studies →

Lead sponsor

Vichy Laboratoires is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and/or female subjects aged 16 to 35 years
  2. Subjects presenting with mild to moderate acne (stage 2 or stage 3 with at least 12 inflammatory lesions on face according to the Global Acne Evaluation)

  3. Female subjects of who:

    • use the same reliable hormonal method (oral contraceptive, implant, intra-uterine device, patch, cervical cap, vaginal ring and injection) for at least 3 months prior to study inclusion and throughout the study or
    • use a reliable non-hormonal contraceptive method (copper intra-uterine device, condoms, diaphragm, cervical cap and spermicide) for at least 1 month prior to study inclusion and throughout the study or
    • have no sexual intercourse and agreeing not to have any throughout the study or
    • are surgically sterile (oophorectomy, hysterectomy or tubal ligation),
  4. Subjects and/or all legal representatives (for minor subjects) who have given written
  5. Subjects who are willing to comply with the study requirements
  6. Subjects with Social Security (health insurance) coverage (according to the French requirements)

Exclusion criteria

Exclusion Criteria:

  1. Subjects with any systemic disorder or face dermatoses other than acne that would in any way confound interpretation of the study results (e.g. atopic dermatitis, eczema, or psoriasis)
  2. Subjects with a condition or receiving a medication and/or with a history of medical/surgical events which, in the opinion of the Investigator, could compromise the safety of the subject or affect the outcome of the study
  3. Subjects with a history of skin cancer
  4. Female subjects who are pregnant (positive urine pregnancy test) or lactating or who are planning to become pregnant during the study
  5. Subjects who have started, stopped or changed of hormonal treatment (, thyroid ...) in the 3 months prior the study inclusion
  6. Subjects with to the active substances of Epiduo (Adapalene and/or benzoyl peroxide) or to one of its
  7. Subjects who are sensitive to peroxides (oxygenated water)
  8. Subjects who have received isotretinoin treatment in the 6 months prior to study inclusion
  9. Subjects who have been exposed to excessive UV light (natural or artificial) in the 1 month prior to the study inclusion or having planned excessive UV light exposure during the study (e.g. ski holidays, holidays in the tropics...)
  10. Subjects who have used systemic drugs for more than 3 consecutive days related to antibiotics, anti-inflammatory, corticoids, anti-acneic in the 4 weeks prior to study inclusion
  11. Subjects who have used topical drugs for more than 3 consecutive days related to antibiotics, anti-inflammatory, corticoids, anti-acneic in the 2 weeks prior to study inclusion
  12. Subjects who have used scrub, anti-seborrheic topical cosmetic products and/or who have applied self-tanning products on face in the 1 week prior the study inclusion
  13. Subjects who have applied cosmetic products for more than 5 consecutive days with alpha hydroxyl-acids, vitamin C, hyaluronic acids in the 1 week prior the study inclusion
  14. Subjects having washed the face and/or the hair the day of the study inclusion (only water is accepted the morning of the study inclusion)
  15. Subjects having applied any topical products on face (including make-up) the day of the study inclusion
  16. Subjects who have planned a major surgery during the study requiring hospitalization under general anesthesia and the use of systemic or topical drugs (e.g. antibiotics, anti-inflammatory) for more than 1 week
  17. Subjects who declare to be deprived of their freedom by administrative or legal decision or who are under guardianship
  18. Subjects who cannot be contacted by telephone in case of emergency
  19. Subjects belonging to the staff of the study centre
  20. Subjects in an exclusion period or participating in another biomedical research study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Salicylic acid & Epiduo 0.1%-2.5% Topical Gel

    Salicylic acid: Once-a-day, on the morning, during 12 weeks. Epiduo gel: Once-a-day, on the evening (before bedtime) during 12 weeks.

    Combination Product: Epiduo · Drug: Salicylic Acid

  • Placebo comparator
    Hydréane légère & Epiduo 0.1%-2.5% Topical Gel

    Hydréane légère: Once-a-day, on the morning, during 12 weeks. Epiduo gel: Once-a-day, on the evening (before bedtime) during 12 weeks.

    Combination Product: Epiduo · Other: Hydréane légère

Interventions

  • Combination productEpiduo

    100 per arm Adapalene/ Benzoyl Peroxide

  • DrugSalicylic Acid

    Salicylic Acid

  • OtherHydréane légère

    moisturizer

06

What researchers measure

Primary outcomes

  1. Evaluation of the anti-acne efficacy 1 (number of the retentional and inflammatory lesions)

    Change in the number of the retentional (open \& closed comedones) and inflammatory lesions (papulae, pustulae \& nodules (if applicable)) on face after a 12-week application period At Week 0 (before any application) and Week 12 (after a 12-week application period), a counting of the retentional (open \& closed comedones) and inflammatory lesions (papulae, pustulae \& nodules (if applicable)) will be performed by a Dermatologist. The counting will be broken down on several parts of the face (forehead, left and right cheeks and chin).

    Time frame: Week 0 (baseline) and Week 12 (final time point)

Secondary outcomes

  1. Evaluation of the anti-acne efficacy 2 (number of the retentional and inflammatory lesions)

    Change in the number of the retentional (open \& closed comedones) and inflammatory lesions (papulae, pustulae \& nodules (if applicable)) on face after 4 and 8-week application period At Week 4 (after a 4-week application) and Week 8 (after a 8-week application period), a counting of the retentional (open \& closed comedones) and inflammatory lesions (papulae, pustulae \& nodules (if applicable)) will be performed by a Dermatologist. The counting will be broken down on several parts of the face (forehead, left and right cheeks and chin).

    Time frame: Week 4 and Week 8 (intermediary times point)

  2. Change in the acne stage on face according to the Global Acne Evaluation scale after 4, 8 and 12-week application period

    At Week 0 (before any application), Week 4 (after a 4-week application period), Week 8 (after an 8-week application period) and Week 12 (after a 12-week application period), determination of the acne stage will be performed by the Dermatologist according to the Global Acne Evaluation scale (score min:0 to score max:5). More the score decreased, more the treatment is efficient.

    Time frame: Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point)

  3. Change in the residual marks visibility after 4, 8 and 12-week application period

    At Week 0 (before any application), Week 4 (after a 4-week application period), Week 8 (after an 8-week application period) and Week 12 (after a 12-week application period), the residual marks visibility of acne (hyperpigmentation) will be assessed under the same conditions by the Dermatologist using the scale below which include 10 grades (0: absence to 9:numerous). More the score decreased, more the treatment is efficient.

    Time frame: Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point)

  4. Change in the pores visibility after 4, 8 and 12-week application period

    At Week 0 (before any application), Week 4 (after a 4-week application period), Week 8 (after an 8-week application period) and Week 12 (after a 12-week application period), the pores visibility will be assessed under the same conditions by the Dermatologist using the scale below which include 10 grades (0: absence to 9:numerous). More the score decreased, more the treatment is efficient.

    Time frame: Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point)

  5. Change in the skin shininess after 4, 8 and 12-week application period

    At Week 0 (before any application), Week 4 (after a 4-week application period), Week 8 (after an 8-week application period) and Week 12 (after a 12-week application period), the skin shininess will be assessed under the same conditions by the Dermatologist using the scale below which include 10 grades (0: absence to 9:high). More the score decreased, more the treatment is efficient.

    Time frame: Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point)

  6. Change in skin greasiness after 4, 8 and 12-week application period

    At Week 0, Week 4, Week 8 and Week 12, instrumental measurements will be performed by a technician/a nurse. The CL measurements (quantity of sebum (casual level)) will be taken using a SEBUMETER®. The unit is in µg sebum/cm² of the skin. Only one measurement per subject will be taken in the middle of the forehead. More the value decreased, less the skin is greasy.

    Time frame: Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point)

  7. Change in skin moisturizing after 4, 8 and 12-week application period

    At Week 0, Week 4, Week 8 and Week 12, instrumental measurements will be performed by a technician/a nurse. The measurements will be taken using a CM 825 PC CORNEOMETER®. The hydratation values are expressed in arbitrary units ranging from approximately 0 to 120. Three measurements per subject will be taken on the right cheekbone. More the value increased, more the skin is moisturize.

    Time frame: Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point)

  8. Change in skin ph after 4, 8 and 12-week application period

    At Week 0, Week 4, Week 8 and Week 12, instrumental measurements will be performed by a technician/a nurse. The measurements will be taken using a SKIN PH METER 900®. The result will be expressed in pH units. Only one measurement per subject will be taken on the left cheek, near to the side of the nose. More the value decreased, more the ph is acid.

    Time frame: Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point)

  9. Total number of hair follicles per cube at a mean depth of 38 µm after a 12-week application period

    At Week 0 and Week 12, instrumental measurements will be performed by investigator at CHU Nantes. Confocal images are obtained by analyzing the reflection of a diode laser in the skin. The lens will be directly applied onto the selected skin area (on 3 nonlesional skin area: forehead, right temple and right mandibular). Confocal images will be analyzed by two confocal microscopy experts.

    Time frame: Week 0 (baseline) and Week 12 (final time point)

  10. Diameter of the infundibulum in µm after a 12-week application period

    At Week 0 and Week 12, instrumental measurements will be performed by investigator at CHU Nantes. Confocal images are obtained by analyzing the reflection of a diode laser in the skin. The lens will be directly applied onto the selected skin area (on 3 nonlesional skin area: forehead, right temple and right mandibular). Confocal images will be analyzed by two confocal microscopy experts.

    Time frame: Week 0 (baseline) and Week 12 (final time point)

  11. Aspect of the border (thickness) (number and percentage) after a 12-week application period

    At Week 0 and Week 12, instrumental measurements will be performed by investigator at CHU Nantes. Confocal images are obtained by analyzing the reflection of a diode laser in the skin. The lens will be directly applied onto the selected skin area (on 3 nonlesional skin area: forehead, right temple and right mandibular). Confocal images will be analyzed by two confocal microscopy experts.

    Time frame: Week 0 (baseline) and Week 12 (final time point)

  12. Onion like appearence (number and percentage) after a 12-week application period

    At Week 0 and Week 12, instrumental measurements will be performed by investigator at CHU Nantes. Confocal images are obtained by analyzing the reflection of a diode laser in the skin. The lens will be directly applied onto the selected skin area (on 3 nonlesional skin area: forehead, right temple and right mandibular). Confocal images will be analyzed by two confocal microscopy experts.

    Time frame: Week 0 (baseline) and Week 12 (final time point)

  13. Presence of amorphous material into the infundibulum (number and percentage) after a 12-week application period

    At Week 0 and Week 12, instrumental measurements will be performed by investigator at CHU Nantes. Confocal images are obtained by analyzing the reflection of a diode laser in the skin. The lens will be directly applied onto the selected skin area (on 3 nonlesional skin area: forehead, right temple and right mandibular). Confocal images will be analyzed by two confocal microscopy experts.

    Time frame: Week 0 (baseline) and Week 12 (final time point)

  14. Signs of inflammation (number and percentage) after a 12-week application period

    At Week 0 and Week 12, instrumental measurements will be performed by investigator at CHU Nantes. Confocal images are obtained by analyzing the reflection of a diode laser in the skin. The lens will be directly applied onto the selected skin area (on 3 nonlesional skin area: forehead, right temple and right mandibular). Confocal images will be analyzed by two confocal microscopy experts.

    Time frame: Week 0 (baseline) and Week 12 (final time point)

  15. Vascularization (number and percentage) after a 12-week application period

    At Week 0 and Week 12, instrumental measurements will be performed by investigator at CHU Nantes. Confocal images are obtained by analyzing the reflection of a diode laser in the skin. The lens will be directly applied onto the selected skin area (on 3 nonlesional skin area: forehead, right temple and right mandibular). Confocal images will be analyzed by two confocal microscopy experts.

    Time frame: Week 0 (baseline) and Week 12 (final time point)

  16. Presence of Demodex mites (number and percentage) after a 12-week application period

    At Week 0 and Week 12, instrumental measurements will be performed by investigator at CHU Nantes. Confocal images are obtained by analyzing the reflection of a diode laser in the skin. The lens will be directly applied onto the selected skin area (on 3 nonlesional skin area: forehead, right temple and right mandibular). Confocal images will be analyzed by two confocal microscopy experts.

    Time frame: Week 0 (baseline) and Week 12 (final time point)

  17. Analysis of the efficacy on the skin quality using a questionnaire

    Subjects will complete an efficacy questionnaire at the last visit (after a 12-week application period of the Investigational Product (cosmetic product \& drug)). The following items will be evaluated by the subjects: 1. Imperfections are less visible 2. The skin is cleansed/purified 3. The complexion is homogeneous / uniform 4. The skin is comfortable 5. The skin is like hydrated 6. The skin is smoother 7. The skin is softer 8. The skin is suppler 9. The skin is less brilliant 10. The skin is matified 11. Excess sebum is reduced 12. The skin has a matte touch 13. The pores of the skin are tightened 14. Redness of the skin are reduced 15. The skin texture is refined 16. The marks of the skin are less visible The following scale will be used: * Agree ("D'accord") * Somewhat agree ("Plutôt d'accord") * Neither agree, nor disagree ("Ni d'accord ni pas d'accord") * Somewhat disagree ("Plutôt pas d'accord") * Disagree ("Pas d'accord")

    Time frame: Week 12 (final time point)

  18. Analysis of the local tolerance using clinical assessments

    At Week 0 (before any application), Week 4 (after a 4-week application period), Week 8 (after an 8-week application period) and Week 12 (after a 12-week application period), a clinical assessment of the face skin condition will be performed by the Dermatologist: * Physical signs: erythema, dryness and scaling * Functional signs\*: tightness, prickling, itching, burning sensation and others The following scale will be used: Rating 0: none ("absence") Rating 1: slight ("léger") Rating 2: moderate ("modéré") Rating 3: severe ("sévère") \* During the study, the subjects will have to record any skin discomfort, intensity (slight, moderate or severe) and duration in their daily log. Functional signs will be assessed by the Dermatologist from a review of the daily log and interrogatory of the subject. In addition, at W12 (after a 12-week application period), the Dermatologist and the subject.

    Time frame: Week 0 (baseline), Week 4 and Week 8 (intermediary times point) and Week 12 (final time point)

  19. Products overall tolerance appreciation by the Dermatologist and the subject

    In addition, at Week 12 (after a 12-week application period), the Dermatologist and the subject will state about the overall tolerance of the IP (cosmetic product \& drug) based on rating scale: * Excellent tolerance * Good tolerance * Medium tolerance * Poor tolerance

    Time frame: Week 12 (final time point)

  20. Analysis of the cosmetic acceptability using a questionnaire

    Subjects will complete a cosmetic acceptability questionnaire concerning the cosmetic product at the last visit. The following items will be evaluated by the subjects: 1. The product is easy to spread 2. The product is easy to apply 3. The product penetrates quickly 4. The color of the product is pleasant 5. The scent of the product is pleasant 6. The aspect of the product is pleasant 7. The texture of the product is pleasant 8. The texture is comfortable 9. The product doesn't leave the skin sticky 10. The product doesn't leave a greasy film on the skin 11. The product leaves a silky effect 12. The product does not go noodles The following scale will be used: * Agree ("D'accord") * Somewhat agree ("Plutôt d'accord") * Neither agree, nor disagree ("Ni d'accord ni pas d'accord") * Somewhat disagree ("Plutôt pas d'accord") * Disagree ("Pas d'accord")

    Time frame: Week 12 (final time point)

  21. Evaluation of the skin microbiota using sampling (if applicable)

    At Week 0 and at Week 12, microbiota sampling will be performed by the same sampler (technician/nurse). Skin microbiota sample will be collected on one test site of 4 cm2 on the middle of the left cheek and using aseptic techniques under sterile airflow generated by a portable hood. According to the results of the primary variable, the Sponsor will decide to go ahead with the microbiota analysis which will be done by INRA Transfert. DNA will be extracted from the swabs. PCR amplification will be performed for each DNA sample. DNA will be PCR amplified. Cleaned pools will be sequenced on the Illumina MiSeq platform. Sequences will be then de-replicated and a database containing one sequence for each operational taxonomic unit will be generated. Interpretation of these results will be done by Mercurialis.

    Time frame: Week 0 (baseline) and Week 12 (final time point)

  22. Analysis of the number of subject with adverse event related to the study product

    Adverse Events will be collected during all the study from Week 0 to Week 12

    Time frame: From Week 0 (baseline) to Week 12 (final time point)

07

Study locations

1 site
  • INTERTEK
    Paris, 75013, France
08

References and documents

Publications

  • Bouloc A, Roo E, Imko-Walczuk B, Moga A, Chadoutaud B, Dreno B. A skincare combined with combination of adapalene and benzoyl peroxide provides a significant adjunctive efficacy and local tolerance benefit in adult women with mild acne. J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1727-1731. doi: 10.1111/jdv.14379. Epub 2017 Jul 7. PubMed 28573779 ↗
  • Muguet Guenot L, Vourc'h Jourdain M, Saint-Jean M, Corvec S, Gaultier A, Khammari A, Le Moigne M, Boisrobert A, Paugam C, Dreno B. Confocal microscopy in adult women with acne. Int J Dermatol. 2018 Mar;57(3):278-283. doi: 10.1111/ijd.13910. Epub 2018 Jan 25. PubMed 29369333 ↗
  • Gollnick HP, Bettoli V, Lambert J, Araviiskaia E, Binic I, Dessinioti C, Galadari I, Ganceviciene R, Ilter N, Kaegi M, Kemeny L, Lopez-Estebaranz JL, Massa A, Oprica C, Sinclair W, Szepietowski JC, Dreno B. A consensus-based practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol Venereol. 2016 Sep;30(9):1480-90. doi: 10.1111/jdv.13675. Epub 2016 May 14. PubMed 27177989 ↗
  • Nast A, Dreno B, Bettoli V, Bukvic Mokos Z, Degitz K, Dressler C, Finlay AY, Haedersdal M, Lambert J, Layton A, Lomholt HB, Lopez-Estebaranz JL, Ochsendorf F, Oprica C, Rosumeck S, Simonart T, Werner RN, Gollnick H. European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version. J Eur Acad Dermatol Venereol. 2016 Aug;30(8):1261-8. doi: 10.1111/jdv.13776. No abstract available. PubMed 27514932 ↗
  • Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Stein Gold LF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016 May;74(5):945-73.e33. doi: 10.1016/j.jaad.2015.12.037. Epub 2016 Feb 17. Erratum In: J Am Acad Dermatol. 2020 Jun;82(6):1576. doi: 10.1016/j.jaad.2020.02.010. PubMed 26897386 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03832647
Lead sponsor
Vichy Laboratoires
Responsible party
Sponsor
First posted
Feb 6, 2019
Start date
Feb 18, 2019
Primary completion
Feb 17, 2020
Completion
Feb 17, 2020
Last update
Oct 18, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Salicylic Acid

Other studies in this condition

Acne Vulgaris →

Other studies from this sponsor

Vichy Laboratoires

Start the discussion